Congenital Syndromes and Leukemia: Clues to Pathogenesis

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 3, 2003, Pages 246-260

  Izraeli, Shai ^a,b,c  

^a Pediatric Hemato Oncology Department   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOM SYNDROME; CHILDHOOD LEUKEMIA; CONGENITAL DISORDER; DISEASE ASSOCIATION; DNA DAMAGE; DOWN SYNDROME; FANCONI ANEMIA; FETUS DEVELOPMENT; FETUS GROWTH; GENETIC DISORDER; HEMATOPOIETIC SYSTEM; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMOGENESIS; MEGAKARYOPOIESIS; NEUROFIBROMATOSIS; NOONAN SYNDROME; PATHOGENESIS; REVIEW;

CHILD; DOWN SYNDROME; EMBRYONIC AND FETAL DEVELOPMENT; HEMATOPOIESIS; HUMANS; LEUKEMIA; MEGAKARYOCYTES; SYNDROME;

EID: 0346394022     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer, 1: 157-162, 2001.
2. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA, 68: 820-823, 1971.
3. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature, 323: 643-646, 1986.
4. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000; 96: 73-92.
5. Sherr CJ and McCormick F. The RB and p53 pathways in cancer. Cancer Cell, 2: 103-112, 2002.
6. D'Andrea AD and Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer, 3: 23-34, 2003.
7. Brady N, Gaymes TJ, Cheung M, et al. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res, 63: 1798-1805, 2003.
8. Poppe B, Van Limbergen H, Van Roy N, et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet, 128: 39-42, 2001.
9. Sanz MM, Proytcheva M, Ellis NA, et al. BLM, the Bloom's syndrome protein, varies during the cell cycle in its amount, distribution, and co-localization with other nuclear proteins. Cytogenet Cell Genet, 91: 217-223, 2000.
10. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer, 3: 155-168, 2003.
11. Perkins EJ, Nair A, Cowley DO, et al. Sensing of intermediates in V(D)J recombination by ATM. Genes Dev, 16: 159-164, 2002.
12. Gellert M. V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem 71: 101-132, 2002.
13. Kirsch IR. Trans-rearrangements and the risk of lymphoid malignancy. Ann Oncol, 8 Suppl 2: 45-48, 1997.
14. Kirsch IR and Lista F. Lymphocyte-specific genomic instability and risk of lymphoid malignancy. Semin Immunol, 9: 207-215, 1997.
15. Liyanage M, Weaver Z, Barlow C, et al. Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood, 96: 1940-1946, 2000.
16. Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell, 86: 159-171, 1996.
17. Liao MJ and Van Dyke T. Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma. Genes Dev, 13: 1246-1250, 1999.
18. Petiniot LK, Weaver Z, Barlow C, et al. Recombinase-activating gene (RAG) 2-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice. Proc Natl Acad Sci USA, 97: 6664-6669, 2000.
19. Izraeli S, Kirsch IR. A molecular genetic analysis of lymphoid neoplasia. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW, eds. Clinical Immunology, Principles and Practice. Vol. 2. London: Mosby, 93.1-93.18, 2001.
20. Arceci RJ. Down syndrome, transient myeloproliferative syndrome, and leukemia: bridging development and neoplasia. J Pediatr Hematol Oncol, 24: 1, 2002.
21. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2: 429-436, 2001.
22. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17: 277-282, 2003.
23. Zipursky A. Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol, 120: 930-938, 2003.
24. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol, 9: 139-149, 1992.
25. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol, 4: 211-230, 1987.
26. Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med, 19: 157-167, vii, 1999.
27. Zipursky A, Brown E, Christensen H, et al. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 21: 97-101, 1997.
28. Speck NA and Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2: 502-513, 2002.
29. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genet, 23: 166-175, 1999.
30. Taketani T, Taki T, Takita J, et al. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia, 16: 1866-1867, 2002.
31. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genet, 32: 148-152, 2002.
32. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet, 361: 1617-1620, 2003.
33. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101: 4301-4304, 2003.
34. Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 101: 4298-4300, 2003.
35. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102: 981-986, 2003.
36. Calligaris R, Bottardi S, Cogoi S, et al. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci USA, 92: 11598-11602, 1995.
37. Chang AN, Cantor AB, Fujiwara Y, et al. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci USA, 99: 9237-9242, 2002.
38. Cantor AB and Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene, 21: 3368-3376, 2002.
39. Hitzler JK. GATA1 - A player in normal and leukemic megakaryopoiesis. Pediatr Res, 52: 831, 2002.
40. Orkin SH, Shivdasani RA, Fujiwara Y, McDevitt MA. Transcription factor GATA-1 in megakaryocyte development. Stem Cells, 16 Suppl 2: 79-83, 1998.
41. Yu C, Cantor AB, Yang H, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med, 195: 1387-1395, 2002.
42. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. Embo J, 16: 3965-3973, 1997.
43. Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood, 100: 2040-2045, 2002.
44. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Genet, 24: 266-270, 2000.
45. Mehaffey MG, Newton AL, Gandhi MJ, et al. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood, 98: 2681-2688, 2001.
46. Elagib KE, Racke FK, Mogass M, et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood, 101: 4333-4341, 2003.
47. Holt SE, Brown EJ, Zipursky A. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome. J Pediatr Hematol Oncol, 24: 14-17, 2002.
48. Ge Y, Jensen TL, Matherly LH, Taub JW. Transcriptional regulation of the cystathionine-beta-synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood, 101: 1551-1557, 2003.
49. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 94: 1393-1400, 1999.
50. Bar-Peled O, Korkotian E, Segal M, Groner Y. Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc Natl Acad Sci USA, 93: 8530-8535, 1996.
51. Peter Y, Rotman G, Lotem J, et al. Elevated Cu/Zn-SOD exacerbates radiation sensitivity and hematopoietic abnormalities of Atm-deficient mice. Embo J, 20: 1538-1546, 2001.
52. Peled-Kamar M, Lotem J, Okon E, et al. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome. Embo J, 14: 4985-4993, 1995.
53. Malkin D, Brown EJ, Zipursky A. The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet Cytogenet, 116: 1-5, 2000.
54. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia, 13: 376-385, 1999.
55. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood, 90: 479-488, 1997.
56. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood, 89: 3534-3543, 1997.
57. Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood, 77: 925-929, 1991.
58. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist, 5: 477-485, 2000.
59. O'Marcaigh AS and Shannon KM. Role of the NF1 gene in leukemogenesis and myeloid growth control. J Pediatr Hematol Oncol, 19: 551-554, 1997.
60. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med, 336:1713-1720, 1997.
61. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92: 267-272, 1998.
62. Watanabe I, Horiuchi T, Hatta N, et al. Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia. Acta Haematol, 100: 22-25, 1998.
63. Miles DK, Freedman MH, Stephens K, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood, 88: 4314-4320, 1996.
64. Cooper LJ, Shannon KM, Loken MR, et al. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood, 96: 2310-2313, 2000.
65. Busque L, Gilliland DG, Prchal JT, et al. Clonality in juvenile chronic myelogenous leukemia. Blood, 85: 21-30, 1995.
66. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. NF1 and GM-CSF interact in myeloid leukemogenesis. Mol Cell, 5: 189-195, 2000.
67. Phillips RA, Hunter JL, Eccleston JF, Webb MR. The mechanism of Ras GTPase activation by neurofibromin. Biochemistry, 42: 3956-3965, 2003.
68. Wittinghofer F. Ras signalling. Caught in the act of the switch-on. Nature, 394: 317, 319-320, 1998.
69. Wittinghofer A. Signal transduction via Ras. Biol Chem, 379: 933-937, 1998.
70. Stirewalt DL, Meshinchi S, Radich JP. Molecular targets in acute myelogenous leukemia. Blood Rev, 17: 15-23, 2003.
71. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003 (Epub ahead of print).
72. Hall A. Signal transduction through small GTPases - a tale of two GAPs. Cell, 69: 389-391, 1992.
73. Hall A. Small GTP-binding proteins - a new family of biologic regulators. Am J Respir Cell Mol Biol, 6: 245-246, 1992.
74. Bernards A. Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim Biophys Acta, 1242: 43-59, 1995.
75. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med, 187: 1893-1902, 1998.
76. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia, 13: 32-37, 1999.
77. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genet, 29: 465-468, 2001.
78. Bader-Meunier B, Tchernia G, Mielot F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr, 130: 885-889, 1997.
79. Choong K, Freedman MH, Chitayat D, et al. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol, 21: 523-527, 1999.
80. Johannes JM, Garcia ER, De Vaan GA, Weening RS. Noonan's syndrome in association with acute leukemia. Pediatr Hematol Oncol. 12: 571-575 1995.
81. Ferraris S, Lanza C, Barisone E, et al. Transient abnormal myelopoiesis in Noonan syndrome. J Pediatr Hematol Oncol, 24: 763-764, 2002.
82. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genet, 34: 148-150, 2003.
83. Avraham H, Price DJ. Regulation of megakaryocytopoiesis and platelet production by tyrosine kinases and tyrosine phosphatases. Methods, 17: 250-264, 1999.
84. Chan RJ, Johnson SA, Li Y, et al. A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis. Blood 2003 (Epub ahead of print).
85. Qu CK, Nguyen S, Chen J, Feng GS. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood, 97: 911-914, 2001.
86. Van Vactor D, O'Reilly AM, Neel BG. Genetic analysis of protein tyrosine phosphatases. Curr Opin Genet Dev, 8: 112-126, 1998.
87. Qu CK, Shi ZQ, Shen R, et al. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol, 17: 5499-5507, 1997.
88. Emanuel PD, Snyder RC, Wiley T, et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood, 95: 639-645, 2000.
89. Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood, 92: 4279-4286, 1998.
90. Iversen PO, Emanuel PD, Sioud M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood, 99: 4147-4153, 2002.
91. Gilliland DG and Tallman MS. Focus on acute leukemias. Cancer Cell, 1: 417-420, 2002.
92. Gilliland DG and Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood, 100: 1532-1542, 2002.